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Abstract 
Transcription factor NRF2 is an important regulator of oxidative stress.  It is involved 
in cancer progression, and has abnormal constitutive expression in acute myeloid 
leukemia (AML). Post-transcriptional regulation by microRNAs (miRNAs) can affect 
the malignant phenotype of AML cells.  In this study we identified and characterised 
NRF2-regulated miRNAs in AML.  A miRNA array identified miRNA expression level 
changes in response to NRF2-knockdown in AML cells.  Further analysis of miRNAs 
concomitantly regulated by knock-down of the NRF2 inhibitor KEAP1, revealed the 
major candidate NRF2-mediated miRNAs in AML.  We identified miR-125B to be 
upregulated by NRF2 and miR-29B to be downregulated by NRF2 in AML.  
Subsequent bioinformatic analysis identified putative NRF2 binding sites upstream of 
the miR-125B1 coding region and downstream of the mir-29B1 coding region. 
Chromatin immunoprecipitation (ChIP) analyses showed NRF2 binds to these 
antioxidant response elements (AREs) located in the 5’ untranslated regions of miR-
125B and miR-29B.  Finally, primary AML samples transfected with anti-miR-125B 
antagomiR or miR-29B mimic showed increased cell death responsiveness either 
alone or co-treated with standard AML chemotherapy.  In summary, we find that 
NRF2 regulation of miR-125B and miR-29B acts to promote leukaemic cell survival, 
and their manipulation enhances AML responsiveness towards cytotoxic 
chemotherapeutics. 
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Introduction 
Acute myeloid leukemia (AML) is a biologically heterogenous disorder that occurs as 
a consequence of a wide variety of genetic abnormalities in haematopoietic 
progenitors that are derived from the bone marrow 1.  However, it is likely that AML 
share various survival pathways downstream of the driver mutations, making the 
existence of common survival pathways and therapeutic targets likely 2. 
 
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a member of the Cap ‘n’ Collar 
basic leucine zipper transcription factor family which protects cells from reactive 
oxygen species (ROS) through the regulation of a number of cytoprotective genes 
including heme oxygenase-1 (HO-1) and NAD(P)H dehydrogenase quinone 1 
(NQO1) 3-5. In cancer NRF2 activation is pro-tumoral in a spectrum of malignancies 
through mutations in NRF2 or its cytosolic inhibitor KEAP1 6-9. However we have 
previously shown that in human AML constitutive activation of the NRF2 signalling 
pathway is not through somatic mutations  of NRF2/Keap1 but as a consequence of 
upstream constitutive activation by NF-κB 10. 11. In addition to contributing to the 
malignant phenotype of AML, we also found that NRF2  contributes to intrinsic 
leukaemia cell resistance to standard front-line chemotherapy agents 12. 10. 
 
miRNAs are short non-coding RNA molecules, approximately 20-30 nucleotides in 
length, that can post-transcriptionally regulate gene expression by binding to the 3’ 
UTR of their target mRNA, thereby repressing gene transcription 13. miRNA 
expression has shown to be dysregulated in a range of cancers, and can act as 
tumour suppressor miRs (by down-regulating oncogenes), or oncomiRs (by targeting 
tumour suppressors) 14.  In light of their role in cancers, miRNA are being 
increasingly studied with the expectation that modulation of their expression can be 
harnessed to improve cancer therapy. A recent study using chromatin 
immunoprecipitation sequencing (ChIP-Seq) experiments on lymphoid cells identified 
high confidence ChIP-Seq peaks for NRF2 binding in the vicinity of several miRNAs, 
suggesting they could be regulated by NRF2 15.  
 
In the present study we look to identify whether NRF2 regulates miRNA in human 
AML. Furthermore we evaluate whether NRF2 regulated miRNA have functional 
importance not only on the biology of the disease but also in the leukemia cell death 
to chemotherapy treatment. 
 
 
 
 
  
Results 
Lentiviral NRF2 knockdown alters miRNA expression 
NRF2 can regulate drug resistance in AML via the induction of cytoprotective and 
detoxification genes 10, 12. To assess whether NRF2 regulates miRNA expression in 
AML we used a commercially available OncomiR collection Cancer miRNA qRT-
PCR Array on THP-1 cells infected with an NRF2 lentiviral knockdown (NRF2-KD) 
and a negative control knockdown (NEG-KD).  Figure 1A shows the change in 
expression of miRNA in response to NRF2-KD compared to the control infected 
NEG-KD. We then treated THP-1 cells with the NRF2 activator, sulforaphane for 6 
hours for comparison. Supplementary table 1 shows the fold increase of miRNA in 
response to both NRF-KD and sulforaphane treatment. From these experiments we 
identified miR-125B, miR-222, miR-221 and miR-223 as potential miRNA up-
regulated by NRF2 and miR-29B and miR-154 as potential miRNA down-regulated 
by NRF2.  Figure 1C shows Western blot analysis of NRF2 and KEAP1 protein 
expression in THP-1 cells in response to NRF2-KD, KEAP1-KD and NEG-KD. 
 
Increased NRF2 activity increases miR-125B and decreases miR-29B 
expression in AML 
We used a qRT-PCR approach to validate the data from the lentiviral array 
experiments 10. THP-1 with NRF2-KD were assayed for miR-125B, miR-221, miR-
222, miR223, miR-29B and miR-154 expression. NRF2-KD results in THP-1 cells 
showing a consistent decrease in miR-125B expression and increasing miR-29B 
expression as well as smaller but not significant fluctuations in miR-221, miR-222, 
miR-223 and miR-154 expression (Figure 1B).  To further assess the role of NRF2 in 
regulating miRNA we increased the activity of NRF2 in THP-1 cells by knockdown of 
the NRF2 inhibitor KEAP1 16. THP-1 were infected with KEAP1 lentiviral knockdown 
(KEAP1-KD). QRT-PCR confirmed the downregulation of KEAP1 and as a positive 
control we showed that KEAP-KD up-regulated the NRF2 target gene HO-1. 
Moreover, miR-125B expression showed a similar increase to HO-1 and miR-29B 
showed a significant decrease in response to KEAP1-KD (Figure 1B). The 
expression of miR-221, miR-222, miR223 and miR-154 were not significantly 
changed in response in NRF2-KD or KEAP1-KD to warrant its inclusion in further 
experiments. Taken together these data identified miR-125B and miR-29B as NRF2 
regulated miRNA in AML. 
  
NRF2 regulates homologs miR-125B1 and miR-29B1 and miR-29A in human 
AML 
Both miR-125B and miR-29B exist as two homologs (Figure 2A). miR-125B1 
(located on chromosome 11) and miR-125B2 (located on chromosome 21), both 
contain identical seed sequences. Both homologs lie in the region of regulatory 
miRNA clusters (miR-100-let-7-a-2) and (LINC00478) respectively, raising the 
possibility that they are regulated or co-regulated by these clusters. miR-29B also 
exists as two homologs, miR-29B1 (located on chromosome 7) and miR-29B2 
(located on chromosome 1) (Figure 2A).  
 
The sequence of the miRNA seed region of both miR-125B1 and 2 is identical. 
Similarly the seed sequence of miR-29B1 is identical to miR-29B2. Therefore we 
used primers designed specifically for the immature miRNA sequences (which does 
differ between the miRNA homologs) to identify which miR-125B and miR-29B 
homologs were being regulated by NRF2. QRT-PCR on lentiviral NRF2-KD THP-1 
cells identified reduced expression of the immature miR-125B1 and increased 
expression of the immature miR-29B1, but no change in the expression of immature 
miR-125B2 and miR-29B2 sequence (Figure 2B and 2C). This suggests that miR-
125B1 and miR-29B1, but not miR-125B2 or miR-29B2, are regulated by NRF2. 
 
To determine whether NRF2 specifically regulated miR-125B1 and miR-29B1 or had 
a more general regulatory effect on their clusters we looked for a differential 
expression on other miRNAs in each of the homolog regions in response to NRF2-
KD. Following NRF2 knock down however there was no difference in the expression 
of miR-100 and let-7a-2 (miR-125B1 cluster; chromosome 11) or miR-99a and let7c 
(miR-125B2 cluster; chromosome 21) (Figure 2B). This implies that NRF2 does not 
regulate these clusters to control miR-125B expression but instead binds to a miR-
125B specific regulatory region. Conversely knockdown of NRF2 elevated miR-29B1 
and miR-29A but had no effect on miR-29B2 and miR-29C (Figure 2C). NRF2 
therefore regulates a defined pattern of expression of the miR-125B1 and miR-29B1 
cluster in human AML. Moreover, results from Figure 1B and Figure 2B and C show 
that changes in total levels of miR-125B and miR-29B are similar to changes in miR-
125B1 and miR-29B1. The main reason for this similarity is that constitutive levels of 
miR-125B2 and miR-29B2 are much lower in AML than there homolog, thus changes 
observed in total miR-125B and miR-29B reflect changes observed in miR-125B1 
and miR-29B1 levels. 
 
 
NRF2 binds to ARE sites in the promoters of miR-125B1 and miR-29B1 
NRF2 acts as a transcription factor by binding to the anti-oxidant response element 
(ARE) region in the promoter regions of its target genes 17, therefore we 
hypothesised that for NRF2 to regulate miR-125B1 and mir-29B1 an ARE site must 
be present in their regulatory regions. To analyse the 5’ miR-125B1 and miR-29B1 
promoter sequence we used transcription factor analysis programmes 
(http://www.gene-regulation.com/cgi-bin/pub/programs /pmatch/bin/p-match.cgi and 
www.genomatix.de/matinspector.html). These analyses identified three potential 
ARE sites within the miR-125B1 promoter and two in the miR-29B1 promoter (Figure 
3A).  
 
To confirm if NRF2 bound to ARE binding sites in the miR-29B1 or the miR-125B1 
promoter a chromatin immunoprecipitation assay (ChIP) was undertaken. Figure 3B 
shows the analysis using antibodies for NRF2 and quantified against control IgG with 
specific primers for ARE1, ARE2 and ARE3 (promoter region of miR-125B1; 
chromosome 11) and ARE4 and ARE5 (promoter region of miR-29B1; chromosome 
7). Recruitment of NRF2 was markedly enhanced to ARE5 in the miR-29B1 
promoter and ARE3 in the miR-125B1 promoter. Next we evaluated the recruitment 
of NRF2 to ARE1, ARE2, ARE3, ARE4 and ARE5 sites in THP-1 cells transfected 
with KEAP1 siRNA. Figure 3C shows that there was increased recruitment of NRF2 
to the ARE3 and ARE5 site, but not the other potential ARE sites in THP-1 cells 
transfected with KEAP siRNA over control siRNA. These observations confirmed that 
NRF2 specifically binds the miR-29B1 ARE5 site and the miR-125B1 ARE3 site. 
  
To establish whether NRF2 functionally controls miR-125B1 expression the miR-
125B1 promoter was cloned into a PGL4 luciferase plasmid and the putative ARE3 
site was mutated (Figure 3D). AML is a disease characterised by constitutive 
activation of NRF2, therefore the luciferase vector PGL4 and PGL4/p125B were 
transfected into THP-1 cells without prior treatment of an NRF2 activator or 
repressor.  We observed an approximate 8 fold increase in luciferase activity in the 
PGL4/p125B plasmid in comparison to the control (Figure 3E). Site directed 
mutagenesis of the ARE3 site in the miR-125B1 promoter corresponded with a 
significant decrease in miR-125B1 promoter activity (Figure 3E). Moreover when we 
co-transfected KEAP1 and NRF2 siRNA with the p125B and p125BNRF2Mut 
plasmids, KEAP1 siRNA induced significant increase in p125B promoter activity and 
NRF2 siRNA inhibited p125B promoter activity. KEAP1 siRNA and NRF2 siRNA had 
no effect on p125BNRF2Mut promoter activity (Figure 3F). Similar experiments on 
the miR-29B1 promoter were technically not possible as the construct was too big 
and would not clone into a luciferase reporter vector. These results demonstrate that 
the ARE3 site in the promoter of mir-125B1 is regulated by NRF2. 
 
NRF2 regulates the expression of miR-125B1 and miR-29B1 in primary human 
AML 
As we have established in AML that high NRF2 mRNA expression causes an 
increase in NRF2 activity 10, and that miR-125B1 and miR-29B1 are regulated by 
NRF2 in AML cell lines we next examined the expression of NRF2, mir-125B1 and 
miR-29B1 in primary human AML cells. NRF2 and miR-125B1 is increased in AML 
compared to normal CD34+ haematopoietic stem cells (HSC), whereas miR-29B1 is 
decreased in AML compared to normal CD34+ HSC (Figure 4A). As total levels of 
miR-125B and miR-29B most likely determine their biological function we analysed 
total levels of miR-125B and miR-29B in AML. Supplementary Figure 2 shows that 
total miR-125B is increased in AML compared to normal CD34+ haematopoietic 
stem cells (HSC), whereas miR-29B is decreased in AML compared to normal 
CD34+ HSC.  Furthermore there is a positive correlation between NRF2 RNA 
expression and mir-125B1 RNA expression, with an inverse correlation between 
NRF2 RNA expression and miR-29B1 RNA expression in primary AML cells (Figure 
4B). To confirm that NRF2 regulates miR-125B1 and miR-29B1 expression in 
primary human AML cells we used NRF2 siRNA to silence NRF2 RNA expression in 
8 AML patient samples.  NRF2 mRNA is significantly knocked down in 7 out of the 8 
AML samples of which the majority also had significantly lower miR-125B1 
expression (Figure 4C). Moreover, NRF2 siRNA in the AML samples increased miR-
29B1 expression (Figure 4C). Together these results show that knockdown of NRF2 
regulates the expression of miR-125B1 and miR-29B1 in primary human AML. 
 
miR-125B antagomiR and miR-29B mimic increases AML apoptosis and 
sensitivity to frontline chemotherapy agents 
Previous studies in AML have suggested that the overexpression of miR-125B plays 
an oncogenic role by repressing apoptosis and the reduction of miR-29B increases 
proliferation and represses apoptosis 18 19. To determine the functional role of 
inhibiting miR-125B and overexpressing miR-29B both alone and in-combination we 
transfected miR-125B antagomiR and miR-29B mimic into THP-1 cells and analysed 
cells for apoptosis by annexin V/PI staining. However, before we did this we showed 
that the concentrations of transfected miR-125B antagomiR and miR-29B mimic 
used manipulated the miRNA levels comparable to that observed in the NRF2-KD 
and KEAP1-KD THP-1 cells (supplementary Figure 1).  THP-1 cells transfected with 
the miR-125B antagomiR or miR-29B mimic showed a small but significant increase 
in annexin V/PI staining in comparison to the control transfection (Figure 5A). 
Moreover, when we co-transfected miR-125B antagomir and miR-29B mimic we 
observed a synergistic increase in annexin V/PI staining in comparison to the control 
(Figure 5A).  
 
Transfection of miR-125B antagomir and miR29B mimic into THP-1 and Kasumi-1 
cells potentiated the cytotoxic effect of the frontline AML chemotherapy agent 
daunorubicin. We observed a significant decrease in the IC50 value for daunorubicin 
in miR-125B and miR-29B transfected cells compared to control cells 
(Supplementary Table 2). Together these results show that miR-125B antagomiR 
together with miR-29B mimic can increase apoptosis of AML cell lines as well as 
increase their sensitivity to AML chemotherapy.  
 
Finally we examined the effects of inhibiting miR-125B and increasing miR-29B 
expression in primary AML cells in comparison to non-malignant primary CD34+ 
HSC. In 6 primary AML patient samples inhibition of miR-125B or increasing miR-
29B showed a significant decrease in cell viability (Figure 5B). Moreover, we also 
observe a much bigger increase in AML apoptosis when AML cells were transfected 
with miR-125B antagomiR together with a miR-29B mimic. A slight decrease in 
CD34+ HSC viability was observed in response to miR-125b antagomiR in 
combination with miR-29B. Finally we compared the viability of primary AML patient 
cells which had normal NRF2 expression (and thus normal miR-125B and miR-29B 
expression) to an AML patient sample which had high NRF2 expression (and thus 
high miR-125B and low miR-29B expression) after treatment with daunorubicin 
(Figure 5C and Table 1 and Supplementary Table 2). AML with normal NRF2 and 
normal miR-125B and miR-29B expression were much more sensitive to 
daunorubicin than AML patient samples which had high NRF2 expression and thus 
high miR-125B and low miR-29B expression. Moreover, when we transfected the 
primary AML that had high NRF2 and high mir-125B and low miR29B with miR-125B 
antagomiR together with miR-29B mimic the result was that sensitivity of these AML 
cells to daunorubicin was increased to a level comparable to AML with normal NRF2 
expression. Since AML#27 has low NRF2 expression over normal CD34+ HSC 
(Table 1), is more sensitive to daunorubicin (Figure 5C), and miR-125B antagomiR 
together with miR-29B mimic had no effect on resistance to daunorubicin (Figure 5C), 
we examined the effect of KEAP1-KD on AML#27 to determine if we could increase 
the activity of NRF2 and increase the chemoresistance of this sample.  Figure 5D 
shows that KEAP1-KD in AML#27. Figure 5E shows that that KEAP1-KD AML#27 is 
more resistant to daunorubicin compared to NEG-KD. However when we transfected 
AML#27 KEAP1-KD cells with control miRNA, miR-125B antagomiR, miR-29B mimic 
and miR-125B antagomiR in combination with miR-29B mimic, only the combination 
decreased resistance to daunorubicin (Figure 5F).  These results demonstrate that 
inhibiting miR-125B and overexpressing miR-29B in combination increases 
apoptosis of primary AML and also increases sensitivity of AML cells to current 
frontline chemotherapy.   
 
miR-29B and miR-125B gene targets in human AML 
Studies have shown that a number of different targets exist for both miR-29B and 
miR-125B in AML (Supplementary table 3). Moreover, some genes are targeted by 
both miR125B and miR29B including CDK6, BCL2, MCL1 and BAK1 18, 20, 21. Here 
we examine the expression of genes listed in Supplementary table 3 for their 
response to transfection of control miRNA, miR-125B antagomiR, miR-29B mimic 
and miR-125B antagomiR in combination with miR-29B mimic. From the miR-29B 
targets Figure 6A shows that MYBL2, AKT2, CDK4 and SP1 are inhibited by miR-
29B mimic in THP-1 cells, however we also observe that AKT2 and CDK4 are further 
inhibited by miR-125B antagomiR in combination with miR-29B mimic. From the 
miR-125B targets Figure 6A shows that MAPK14 and STAT3 show an increase in 
mRNA in response to miR-125B antagomiR. We observe a significant increase in 
BAK1 mRNA expression in response to miR-125B antagomiR, which is not effected 
by the addition of miR-29B mimic.  Finally we observe a decrease in BCL2 
expression in response to miR-29B mimic which is slightly reversed by the addition 
of miR-125B antagomiR. To determine if the effects observed in mRNA was 
translated into protein in THP-1 cells transfected with miR-125B antagomiR, miR-
29B mimic and miR-125B antagomiR in combination with miR-29B mimic we 
examined AKT2, STAT3 and BAK1. Figure 6B shows a reduction in AKT2 protein 
expression in response to miR-29B mimic and miR-125B antagomiR in combination 
with miR-29B mimic. STAT3 showed a slight increase in response to miR-29B mimic 
and miR-125B antagomiR in combination with miR-29B mimic. BAK1 showed an 
increase in response to miR-125B antagomir and miR-125B antagomiR in 
combination with miR-29B mimic. Together these results show that mir-29B and 
miR-125B regulate a number of genes involved in proliferation and apoptosis in AML 
cells.  
 
Discussion 
Our understanding of the role of non-coding RNA molecules in diseases such as 
cancer is presently in its infancy. To date miRNA have been shown to have a 
significant role in cancer biology through the regulation of both tumour suppressors 
and oncogenes. Less is known however about the upstream control of miRNA 
expression in cancer and the biological processes which control miRNA expression. 
In AML differential expression of a number of miRNA has been reported to be 
associated with the malignant phenotype but as yet the upstream mechanisms by 
which this is controlled have yet to be described. As we have previously identified 
NRF2 as an important regulator of cell survival in AML the aim of the present study 
was to investigate the ability of NRF2 to effect miRNA expression and furthermore 
define the function of these miRNA in human AML both in a resting state and in 
response to front line chemotherapeutic agents.  
 
Through gene expression data and multiple transcription factor binding assays we 
found that NRF2 up-regulates mir-125B1 and down regulates miR-29B1 though 
binding to specific ARE sites in the miR-125B1 and miR-29B1 regulatory regions. 
Furthermore we observed that by decreasing the expression of miR-125B and 
increasing the expression of miR-29B the cells become more sensitive to apoptotic 
stimuli. These findings are in keeping with previous observations that miR-29B and 
miR-125B regulate the expression of multiple survival pathways in AML. Specifically 
miR-125B acts as an oncomiR in AML by down-regulating various tumour 
suppressor genes including BAK1, BMF and STAT3 20-22. miR-29B act as a tumour 
suppressor by inhibiting the expression of pro-survival genes including AKT2, BCL2, 
CDK4 and SP123-25. The global repression of miR-125B targets and elevation of miR-
29B targets genes would aid the uncontrolled proliferative phenotype of AML. 
Therefore, in Figure 6A and 6b we analyse the targets of miR-29B and miR-125B in 
AML cells transfected with corresponding mimic and antagomir, both alone and in 
combination. We observe changes in a number of genes including AKT2, CDK4, 
MAPK14, STAT3, BCL2 and BAK1. Interestingly, AKT2 and CDK4 are targets of 
miR-29B only, however when we co-transfect miR-125B antagomir and miR-29B 
mimic we do observe a further reduction over miR-29B mimic only. There are no 
miR-125B sites within these two genes suggesting that the combined observations 
are due to off target effects.   Together the cumulative repression of miR-29B and 
the over expression of miR-125B significantly contributes to leukemia cell 
proliferation within the bone marrow niche.  
 
In the clinic we observe that once AML is established the principle cause of 
refractory or relapsed disease is resistance to our currently used drugs 26. We have 
previously shown that high NRF2 activity in AML can protect AML blasts from 
chemotherapy induced cytotoxicity via the regulation of anti-oxidant genes. Here we 
extend the chemo-protective role of NRF2 in human AML via regulation of miR-125B 
and miR-29B, and furthermore explain the previous observations that both high miR-
125B and low miR-29B are associated with chemotherapy resistance 21, 27-29. As we 
found that miR-125B antagomiR and miR-29B mimic in combination enhance the 
sensitivity of AML cells to chemotherapy, targeting these miRNA, or NRF2 (the 
transcription factor which controls there expression), is a biologically plausible novel 
strategy for AML therapy.  
 Transcription factors are generally structured in context of networks. In AML miR-
29B down regulation has been found to be associated with high C-MYC levels as 
well as high SP1 and NF-κB 23, 24. Furthermore NF-κB, JUN and C-MYC have been 
linked to increased NRF2 activity in human cancer (including AML) 10, 30 and NRF2 
has been shown to transcriptionally regulate miR-125B in kidney epithelia cells in 
response to cisplatin-induced toxicity 31. Taken together it is likely that NRF2 plays a 
central role in the complex network regulating miR-29B and miR-125B in human 
AML.   
 
We also highlight that other miRNA may be regulated by NRF2. The array data 
shown as supplementary Table 1 shows that some miRNAs are down-regulated in 
response to NRF2-KD and increased in response to sulforaphane. This list  includes 
miR-222, miR221, miR-223 miR-23a, miR-195 and miR-196a. Of particular interest 
from this group is miR-222, miR-221 and miR223  which have been shown to be 
highly expressed in AML compared to other leukaemias 32. Moreover, we also noted 
that high NRF2 activity caused a decrease in the expression of miRNA which 
includes miR-154, miR146a and miR-181B. All these miRNA have been shown to be 
of interest in AML with miR-146a being shown to have low expression in AML which 
correlates with high expression of its target gene CXCR4 33, which in a separate 
study has been shown to be regulated by NRF2 in human HSC 34.  Consequently in 
human AML, NRF2 not only regulates key genes involved in the reaction to oxidative 
stress but also regulates miRNA which appear to have a broader impact on gene 
expression and regulation.  
 
In summary here we report the first description of upstream miRNA regulation by 
NRF2 in a human cancer and its downstream cyto-protective consequences. In 
doing so we not only provide novel mechanistic insight into the pro-tumoral 
consequences of the constitutive NRF2 expression in AML, we propose that 
targeting the NRF2 regulation of these miRNA (or the miRNA directly) would be a 
biologically plausible therapeutic strategy to increase the effectiveness of 
chemotherapy in human AML. 
 
 
  
Experimental Procedures 
Materials 
The AML-derived cell lines were obtained from the European Collection of Cell 
Cultures where they are authenticated by DNA-fingerprinting.  In the laboratory they 
are used at low passage number for a maximum of 6 months post-resuscitation, 
testing regularly for Mycoplasma infection. All primers were purchased from 
Invitrogen. AKT2, STAT3 and BAK1 antibodies were purchased from Cell Signalling 
technology (Cambridge, MA). NRF2 and KEAP1 antibodies were purchased from 
Santa Cruz Biotechnology. All other reagents were obtained from Sigma-Aldrich (St 
Louis, MO), unless indicated. To assess whether NRF2 regulates miRNA expression 
in AML we used commercially available OncomiR collection Cancer miRNA qRT-
PCR Array.  
 
Primary AML cell culture 
AML cells were obtained from patients bone marrow or blood following informed 
consent and under approval from the UK National Research Ethics Service 
(LRECref07/H0310/146).  For primary cell isolation, heparinized blood was collected 
from volunteers and human peripheral blood mononuclear cells (PBMCs) isolated by 
Histopaque (Sigma-Aldrich, UK) density gradient centrifugation. AML samples that 
were less than 80% blasts were purified using the CD34 positive selection kit 
(Miltenyi Biotec) (denoted by * in Table 1).   Cell type was confirmed by microscopy 
and flow cytometry.  We obtained hematopoietic CD34+ cells from two sources, 
Stem Cell Technologies and volunteers.  Positive selection of CD34+ cells were 
isolated from PBMCs using a CD34 positive selection kit (Miltenyi Biotec, Auburn, 
CA). For all CD34+ experiments at least three different donors were used to obtain 
the results presented in this paper.  Cell type was confirmed by microscopy and flow 
cytometry.   
 
RNA extraction and real time PCR (RT-PCR) 
Total mRNA extraction was carried out using mirVana miRNA isolation kit (Ambion) 
and reverse transcribed using the miRscript II RT kit (Qiagen). All mature miRNA 
were normalised to RNU6B and immature miRNA and mRNA were normailsed to 
GAPDH for qRT-PCR as described previously 35. qRT-PCR was carried out using 
SYBR green technology (Qiagen). The samples were preamplified at 95C for 2 
minutes, after which was amplified for 45 cycles at 95C for 15 seconds, 60C for 10 
seconds and 72C for 10 seconds. The qRT-PCR was performed on the 
LightCycler480 (Roche). 
 
Virus construction and infection 
Lentiviruses containing microRNA sequence miRNA-Nrf2 (5 ′ -TTAATGAGTTCAC 
TGTCAACT-3’), miRNA-KEAP1 (5’-GTTTTGGCCACTGACTGAC-3’) and miR-NEG 
were constructed and produced as described previously 36. For transduction THP-1 
cells and AML blasts cells were plated onto 12-well plates (5 × 104 cells/well) and 
infected with lentiviruses (multiplicity of infection of 15) with 8 µg/mL Polybrene™. 
Transduced cells were analyzed by flow cytometry (Accuri), real-time PCR (Roche) 
and Western Blotting. 
 
Transfections 
AML transfections were carried out with 2x106 cells using the Amaxa Nucleofactor Kit 
II. Control miR, miR-29B mimic and miR-125B antagomiR, control siRNA, KEAP1 
and NRF2 siRNA were purchased from Invitrogen were transfected in at a 
concentration of 45 nm. For Control miR the miR-mimic negative control and the 
anti-miR miRNA Inhibitor negative control for single experiments and combined miR-
mimic negative control and the anti-miR miRNA inhibitor negative control in 
combined experiments were used. For all gene expression experiments the cells 
were incubated for 24 hours post transfection before RNA extraction. For the cell 
viability assays AML cell were incubated for 48 hours post transfection. For reporter 
assays 0.5μg of PGL4 reporter and pRL-TK control constructs were co-transfected 
into THP-1. Transfected cells were incubated for 24 hours before the indicated 
treatments. For reporter assay cells were treated with Dual-Luciferase reporter assay 
system (Promega). 
 
Western Blotting 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot 
analyses were performed as described previously. Briefly, whole cell lysates as well 
as nuclear and cytosolic were extracted and sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis separation performed 37. Protein was transferred to nitrocellulose 
and Western blot analysis performed with the indicated antisera according to their 
manufacturer’s guidelines.  
 
Cloning of miR-125B promoter construct 
To generate the p125B promoter construct containing ARE3 a DNA fragment 
containing 2.6 kb of the human 125b promoter region was amplified from genomic 
DNA with PCR and specific primers 5-TGAGAGGAGCGCAACAATG-3 ′  reverse 
primer and 5′-AGAAAGGCCACCAAGATTCAC-3′ forward primer. The fragment was 
cloned into the PGL4.11 basic plasmid (Promega). To generate mutated NRF2 
construct (p125B NRF2 MUT) the sense PCR primer used was 5 ′ -
GCTGTGGCTGtTTTGTtATTCTCTTTGACTAG-3 ′ . This mutation was introduced 
with the QuikChange XL Site-Directed Mutagenesis Kit (Agilent). 
 
Cell viability and apoptosis assays 
THP-1, Kasumi-1, primary CD34+ HSC and primary AML cells were transfected with 
control miR (miR-mimic negative control and the anti-miR miRNA Inhibitor negative 
control for single experiments and combined miR-mimic negative control and the 
anti-miR miRNA Inhibitor negative control in combined experiments), miR-29B mimic 
and miR-125B antagomiR and combined miR-29B mimic and miR-125B antagomiR 
for 24 h. THP-1 cells were analysed for apoptosis using PI/Annexin V staining.  THP-
1, Kasumi-1, primary CD34+ HSC and primary AML transfected cells were treated 
with different concentrations of chemotherapy agents and incubated for 48 h then 
viable cells measured with Cell-Titre GLO (Promega).  
 
Chromatin immunoprecipitation assay  
THP-1 cells were transfected with control siRNA or KEAP1 siRNA 24 h before the 
cells were fixed with 1% formaldehyde in medium for 10 min at room temperature. 
The sonication conditions were optimized to determine generation of DNA fragments 
between 300 and 600 base pairs in length. Chromatin was immunoprecipitated with 
IgG, anti-NRF2 (Cell Signalling). The association of NRF2 was measured by RT-
PCR on immunoprecipitated chromatin using primers spanning the ARE sites 
described in Figure 3A and supplementary table 4. 
 
Statistical analyses 
Student’s T test was performed to assess statistical significance from controls. 
Results with P < 0.05 were considered statistically significant (*). Results represent 
the mean ± SD of 3 independent experiments.  
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Legends 
 
Figure 1. miRNA profiling of AML cells in response lentiviral NRF2 knockdown.  
(A) THP-1 cells were transduced with NEG (NEG-KD) and NRF2 (NRF2-KD) 
targeted miRNA lentiviral constructs. QRTPCR analysis of 92 cancer-associated 
miRNAs in NRF2-KD THP-1 cells.  Values represent change in qRT-PCR cycle 
threshold normalized to RNU6B (ΔCT). Dashed line indicates no change in 
expression. A red circle indicates miR-125B, miR221, miR-223, miR222, miR29B 
and miR154. (B) QRT-PCR of miR-125B, miR221, miR-223, miR222, miR29B, 
miR154, NRF2, KEAP1 and HO1 in THP-1 cells transduced with NEG-KD, NRF2-KD 
or KEAP1-KD. Values represent fold change in RNA expression over NEG-KD 
control. (C) THP-1 were transduced with NEG-KD, NRF2-KD or KEAP1-KD before 
cells were analysed for NRF2 and KEAP1 using Western blotting. Blots were 
reprobed for βactin to show sample loading. The numbers under the blots indicate 
densitometry analysis of the blots using Image J software, and the results are 
expressed as fold change relative to the NEG-KD control. 
 
 
Figure 2. NRF2 regulates homologs miR-125B1 and miR-29B1 and miR-29A in 
human AML.  (A) Schematic representation of the miRNA chromosomal positioning 
of miR-125B (1 and 2) and miR-29B (1 and 2). (B) Total RNA was extracted from 
THP-1 transduced with NEG-KD and NRF2-KD and examined for miRNA expression 
including immature miR-125B1, miR-125B2 RNA and HO-1 mRNA expression. (C) 
Total RNA was extracted from THP-1 transduced with NEG-KD and NRF2-KD and 
examined for miR-29A and miR-29C expression including immature miR-29B1, miR-
29B2 RNA and HO-1 mRNA expression.  
 
Figure 3. NRF2 binds to ARE sites in the promoters of miR-125B1 and miR-
29B1. (A) Schematic presentation of ARE binding sequences in the 5’ region of miR-
29B1 on chromosome 7 and miR-125B1 on chromosome 11. (B) Chromatin 
immunoprecipitation (ChIP) analysis of the miR-29B1 and miR-125B1 promoter 
using antibodies against NRF2 and normal rabbit IgG was used as a control. 
QRTPCR was performed in triplicate on immunoprecipitated DNA and input DNA.  
Data presented as percent of input. * indicates P < 0.05 between the different 
treatment groups (C) THP-1 cells were transfected control siRNA and KEAP1 siRNA 
for 24 h and ChIP performed. Real-time PCR was performed in triplicate on 
immunoprecipitated DNA and input DNA.  Data presented as percent of input. * 
indicates P < 0.05 between the different treatment groups. (D) Schematic 
representation of mutated miR-125B promoter sequence. (E) THP-1 cells were 
transiently transfected with 0.5 µg of each promoter construct including control 
plasmid and pRL-TK for normalization of transfection efficiency. Cell extracts were 
harvested, and luciferase assays were performed. Values are the means ± S.D., 
n = 4. * indicates P < 0.01 of deleted ARE against PGL4 control. (F) Control, KEAP1 
and NRF2 siRNA were transfected at the same time as p125b and p125bNRF2 MUT 
and incubated for 48 h Cell extracts were harvested, and luciferase assays were 
performed. Values are the means ± S.D., n = 4. * indicates P < 0.01 of KEAP1 
siRNA and NRF2 siRNA against NEG siRNA control.  
 
Figure 4. NRF2 regulates miR-29B1 and miR-125B1 in primary AML. (A) Total 
RNA was extracted from patient AML blasts (n=18) and CD34+ HSC (n=8).  NRF2, 
miR-29B1 and miR-125B1 RNA expression levels were measured using QRTPCR. 
(B) Pearson’s correlation analysis between miR-125B1 or miR-29B1 and NRF2 
mRNA expression in human primary AML cells. (C) Control and NRF2 siRNA were 
transfected into primary blasts (n=7) for 48 h and RNA extracted. RNA was analysed 
for NRF2, miR-125B1 and miR-29B RNA expression. Values are the means ± S.D., 
n = 3.  
 
Figure 5. miR-125B antagomiR and miR-29B mimic induces apoptosis of AML 
cells and increases there sensitivity to AML chemotherapy. (A) THP-1 were 
transfected with control miRNA, miR-125B antagomiR (α125B), miR-29B mimic (29B 
mimic) and miR-125B antagomiR in combination with miR-29B mimic for 48 h before 
cells were analysed for apoptosis by PI/Annexin V staining. (B) AML Blasts (n=6) 
and CD34+ (n=4) were transfected with control miRNA, miR-125B antagomiR and 
miR-29B mimic and miR-125B antagomiR in combination with miR-29B mimic for 24 
h and then assessed for cell viability by Cell Titer-GLO. (C) AML blasts and CD34+ 
cells were transfected with control miRNA (miR-mimic negative control and the anti-
miR miRNA Inhibitor negative control for single experiments and combined miR-
mimic negative control and the anti-miR miRNA inhibitor negative control in 
combined experiments), miR-125B antagomiR, miR-29B mimic and miR-125B 
antagomiR in combination with miR-29B mimic for 24 h before the addition of 
increasing doses of daunorubicin for 48 h. Cells assessed for viability by Cell Titer-
GLO. (D) AML#27 was transduced with NEG-KD and KEAP1-KD for 48 hours before 
cells before the addition of increasing doses of daunorubicin for 48 h before cells 
were analysed for KEAP1 using Western blotting. Blots were reprobed for βactin to 
show sample loading. (E) AML#27 was transduced with NEG-KD and KEAP1-KD for 
48 hours before the addition of increasing doses of daunorubicin for 48 h Cells 
assessed for viability by Cell Titer-GLO. (F) AML#27 was transduced with KEAP1-
KD for 48 hours before cells were transfected with control miRNA, miR-125B 
antagomiR, miR-29B mimic and miR-125B antagomiR in combination with miR-29B 
mimic for 24 h followed by the addition of increasing doses of daunorubicin for 48 h. 
Cells assessed for viability by Cell Titer-GLO. 
 
 
Figure 6. miR-125B antagomiR and miR-29B mimic gene targets in AML cells. 
(A) THP-1 were transfected with control miRNA, miR-125B antagomiR (α125B), miR-
29B mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B 
mimic for 48 h before cells were analysed for target gene expression using QRT-
PCR. (B) THP-1 were transfected with control miRNA, miR-125B antagomiR (α125B), 
miR-29B mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B 
mimic for 48 h before cells were analysed for AKT2, STAT3 and BAK1 using 
Western blotting. Blots were reprobed for βactin to show sample loading. The 
numbers under the blots indicate densitometry analysis of the blots using Image J 
software, and the results are expressed as fold change relative to the negative 
control.  
 
Table 1. AML patient sample information, NRF2 RNA expression and relative 
miR-125B1 and miR-29B1 RNA expression levels. This table defines the nature of 
the AML disease including WHO diagnosis and cytogenetics.  NRF2, miR125B1 and 
miR-29B1 RNA expression levels over CD34+ control cells 
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 Number Age Gender WHO diagnosis Cytogenetics 
% 
Blasts 
Fold NRF2 
mRNA over 
CD34+ 
 Fold RNA over 
CD34+  
miR-125B1  miR-29B1
AML#1 49 M AML with maturation normal 80 3.35 6.57 0.04
AML#2 39 M AML with maturation normal 65* 6.89 12.33 0.11 
AML#3 64 M AML with RUNX1-RUNX1T1 t(8;21) 85 1.26 1.09 1.01 
AML#4 92 F 
AML with myelodysplasia related 
changes 
not available 70* 1.23 1.70 0.20 
AML#5 82 F AML with MDSrelated changes deletion 13 85 3.39 3.20 0.07 
AML#6 46 F AML with maturation +4,+8, t(9;22) 70* 4.99 12.51 0.10 
AML#7 66 F AML with maturation t(2;12) 65* 1.23 5.22 0.27 
AML#8 78 M AML with MDS related changes not available 85 4.19 9.85 0.01 
AML#9 57 M AML without maturation not available 95 4.35 4.59 0.09 
AML#10 27 M AML with RUNX1-RUNX1T1 t(8;21) 60* 4.99 10.93 0.08 
AML#11 25 M AML with maturation normal 50* 4.81 6.63 0.37 
AML#12 61 M Relapsed AML without maturation not avaiable 95 1.96 1.07 0.71 
AML#13 28 F 
Acute Monoblastic and Monocytic 
Leukaemia 
normal 90 4.68 6.52 0.33 
AML#14 31 F AML without maturation trisomy 8 75* 2.73 6.37 0.03 
AML#15 84 M Acute meyloid leukaemia, NOS not available 70* 3.99 2.43 0.24 
AML#16 53 M 
AML with t(6;9)(p23;q34);DEK-
NUP214 
t(6;9) 65* 3.25 9.13 0.24 
AML#17 51 F AML with maturation normal 40* 4.54 3.45 0.02 
AML#18 47 M 
Acute myeloid leukaemia without 
maturation 
not avaiable 90 4.20 2.07 1.33 
AML#19 77 F AML with maturation normal 70* 2.78 7.70 0.21
AML#20 62 M AML with maturation complex 55* 2.96 2.67 0.59 
AML#21 70 M AML with minimal differentiation normal 95 2.01 1.98 0.64
AML#22 65 F AML with maturation Normal 40* 1.44 2.75 0.24 
AML#23 77 M Therapy related AML complex 70* 3.24 3.10 0.24 
AML#24 40 F AML with minimal differentiation normal 90 1.77 3.23 1.09 
AML#25 70 M AML without maturation complex 95 3.18 6.54 0.42
AML#26 91 F AML NOS not available 75* 1.08 1.63 0.97 
AML#27 59 F 
AML with t(8;21)(q22;q22); 
RUNX1-RUNX1T1 
t(8;21) 85 1.17 1.44 0.53 
 
Table 1. AML patient sample information, NRF2 RNA expression and relative miR-125B1 and miR-29B1 
RNA expression levels. This table defines the nature of the AML disease including WHO diagnosis and 
cytogenetics.  NRF2, miR125B1 and miR-29B1 RNA expression levels over CD34+ control cells 






